UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange
Act of 1934
Date of Report (Date of earliest event reported) August 8, 2024
GlobeStar
Therapeutics Corporation
(Exact name of registrant as specified in its charter)
Wyoming
|
333-170315
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number) |
(IRS Employer Identification No.) |
1280 Lexington Ave.
FRNT 2 #1290
New York,
NY 10028
(Address of principal executive offices)(Zip Code)
509.531.1671
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange
Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on
which registered |
Common
|
GSTC
|
N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined
in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2
of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected
not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section
13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 8, 2024, GlobeStar Therapeutics Corporation, a Wyoming
corporation (the “Company”) received notice of the resignation of Robert Chicoski as Chief Financial Officer of the
Company. In connection with his resignation, Mr. Chicoski relinquished his role as the Company’s “Principal Financial
and Accounting Officer” for Securities and Exchange Commission reporting purposes. Mr. Chicoski’s decision to resign
was not the result of any disagreement with the Company.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
GlobeStar Therapeutics Corporation |
|
|
|
|
Date: October 28, 2024 |
By: /s/ James C. Katzaroff |
|
|
Name: James C. Katzaroff
Title: Chief Executive Officer |
- 2 -